敲减lncRNA RP11-626G11.3通过调控miR-532-3p抑制人肾癌细胞系的增殖和迁移

doi:10.16352/j.issn.1001-6325.2023.10.1498

基础医学与临床 ›› 2023, Vol. 43 ›› Issue (10): 1498-1504.doi: 10.16352/j.issn.1001-6325.2023.10.1498

敲减lncRNA RP11-626G11.3通过调控miR-532-3p抑制人肾癌细胞系的增殖和迁移

王文龙¹, 唐一君^2*, 王青兵¹, 陈科³, 程继强¹

河南科技大学附属安阳市肿瘤医院 1.外科五病区;
2.肿瘤内科五病区,河南安阳 455000;
3.华中科技大学附属协和医院肾内科,湖北武汉 430022

收稿日期:2023-01-17 修回日期:2023-07-18 出版日期:2023-10-05 发布日期:2023-10-05
通讯作者: *tyjnanyang@163.com
基金资助:
国家自然科学基金(81772721)

Knockdown of lncRNA RP11-626G11.3 inhibits proliferation and migration of human renal carcinoma cell lines through regulating miR-532-3p

WANG Wenlong¹, TANG Yijun^2*, WANG Qingbing¹, CHEN Ke³, CHENG Jiqiang¹

1. Department of the Fifth Ward of Surgery;
2. Department of the Fifth Ward of Medical Oncology, Anyang Cancer Hospital Affiliated to Henan University of Science and Technology, Anyang 455000;
3. Department of Nephrology, Union Hospital Affiliated to Huazhong University of Science and Technology, Wuhan 430022, China

Received:2023-01-17 Revised:2023-07-18 Online:2023-10-05 Published:2023-10-05
Contact: *tyjnanyang@163.com

摘要/Abstract

摘要： 目的研究长链非编码RNA(lncRNA) RP11-626G11.3在肾癌组织和细胞系中的表达,探究敲减RP11-626G11.3对肾癌细胞生物学行为的影响。方法用GEPIA数据库分析RP11-626G11.3在肾癌组织和癌旁组织中的表达情况,用TCGA数据库分析RP11-626G11.3表达水平与肾癌患者生存期的关系。QPCR检测RP11-626G11.3在多种肾癌细胞系中的表达。选择RP11-626G11.3表达最高的肾癌细胞系,分别转染对照质粒(si-NC组)和RP11-626G11.3沉默质粒(si-RP11-626G11.3组)。MTT法和细胞划痕实验检测细胞的增殖和迁移。通过生物信息学方法找到与RP11-626G11.3结合的微小RNA(miRNA),并用双荧光素酶报告实验进行验证。QPCR检测两组细胞中miR-532-3p的表达。Western blot检测两组细胞中Wnt/β-catenin信号通路蛋白的表达。结果与癌旁组织相比,肾癌组织中RP11-626G11.3 表达量上调(P＜0.01)。与RP11-626G11.3高表达的患者相比,RP11-626G11.3低表达的患者生存期较长(P＜0.01)。与永生化肾小管上皮细胞相比,肾癌细胞系中RP11-626G11.3表达量均上调(P＜0.01),OS-RC-2细胞中RP11-626G11.3的表达量最高(P＜0.01)。与si-NC组相比,si-RP11-626G11.3组OS-RC-2细胞活力明显降低(P＜0.05),细胞迁移率明显降低(P＜0.01)。RP11-626G11.3靶向结合miR-532-3p(P＜0.01)。相比si-NC组,si-RP11-626G11.3组OS-RC-2细胞中miR-532-3p表达明显上调(P＜0.01),Wnt/β-catenin信号通路蛋白β-catenin、Axin2、C-myc、cyclin D1、MMP7表达水平下降。结论 RP11-626G11.3在肾癌组织和细胞系中表达量升高,敲减RP11-626G11.3通过调控miR-532-3p表达抑制肾癌细胞系的增殖和迁移。

关键词: 肾肿瘤, RP11-626G11.3, miR-532-3p, 增殖, 迁移

Abstract: Objective To study the expression of long-chain non-coding RNA (lncRNA) RP11-626G11.3 in renal cancer tissues and cell lines, and to explore the effect of knockdown of RP11-626G11.3 on the biological behavior of renal cancer cells. Methods The GEPIA database was used to analyze the expression of RP11-626G11.3 in renal cancer tissues and adjacent tissues, and the TCGA database was used to analyze the relationship between the expression of RP11-626G11.3 and the survival time of renal cancer patients. The expression of RP11-626G11.3 in various renal cancer cell lines was detected by qPCR. The renal cancer cells with the highest expression of RP11-626G11.3 were selected and transfected with control plasmid (si-NC group) and RP11-626G11.3 silencing plasmid (si-RP11-626G11.3 group). Cell proliferation and migration were examined by MTT assay and cell scratch assay. The microRNA (miRNA) binding to RP11-626G11.3 was found by bioinformatics method, and verified by dual-luciferase reporter gene experiment. The expression of miR-532-3p in the two groups of cells was detected by qPCR. Western blot was used to detect the expression levels of Wnt/β-catenin signaling pathway in the two groups of cells. Results Compared with adjacent tissues, the expression of RP11-626G11.3 was up-regulated in renal cancer tissues (P＜0.01). Compared with patients with high expression of RP11-626G11.3, patients with low expression of RP11-626G11.3 had a longer survival time (P＜0.01). Compared with immortalized renal tubular epithelial cells, the expression of RP11-626G11.3 was up-regulated in renal cancer cell lines (P＜0.01), and the expression of RP11-626G11.3 was the highest in OS-RC-2 cells (P＜0.01). Compared with si-NC group, the viability of OS-RC-2 cells in si-RP11-626G11.3 group was significantly decreased (P＜0.05) with decreased cell migration rate(P＜0.01). RP11-626G11.3 was found to target at miR-532-3p (P＜0.01). Compared with the si-NC group, the expression of miR-532-3p in OS-RC-2 cells in the si-RP11-626G11.3 group was significantly up-regulated (P＜0.01), and the Wnt/β-catenin signaling pathway proteins β-catenin, Axin2, C-myc, cyclin D1 and MMP7 decreased. Conclusions The expression of RP11-626G11.3 is increased in renal cancer tissues and cell lines. Knockdown of RP11-626G11.3 inhibits the proliferation and migration of renal cancer cells by regulating the expression of miR-532-3p.

Key words: renal tumor, RP11-626G11.3, miR-532-3p, proliferation, migration

中图分类号:

R737.11

王文龙, 唐一君, 王青兵, 陈科, 程继强. 敲减lncRNA RP11-626G11.3通过调控miR-532-3p抑制人肾癌细胞系的增殖和迁移[J]. 基础医学与临床, 2023, 43(10): 1498-1504.

WANG Wenlong, TANG Yijun, WANG Qingbing, CHEN Ke, CHENG Jiqiang. Knockdown of lncRNA RP11-626G11.3 inhibits proliferation and migration of human renal carcinoma cell lines through regulating miR-532-3p[J]. Basic & Clinical Medicine, 2023, 43(10): 1498-1504.

参考文献 15

[1]	Caliò A, Harada S, Brunelli M, et al. TFEB rearranged renal cell carcinoma. a clinicopathologic and molecular study of 13 cases. Tumors harboring MALAT1-TFEB, ACTB-TFEB, and the novel NEAT1-TFEB translocations constantly express PDL1[J]. Mod Pathol, 2021, 34: 842-850.
[2]	Gu Y, Niu S, Wang Y, et al. DMDRMR-mediated regulation of m6A-modified CDK4 by m6A reader IGF2BP3 drives ccRCC progression[J]. Cancer Res, 2021, 81: 923-934.
[3]	Zhou Q, Li D, Zheng H, et al. A novel lncRNA-miRNA-mRNA competing endogenous RNA regulatory network in lung adenocarcinoma and kidney renal papillary cell carcinoma[J]. Thorac Cancer, 2021, 12: 2526-2536.
[4]	Wu G, Xia P, Yan S, et al. Identification of unique long non-coding RNAs as putative biomarkers for chromophobe renal cell carcinoma[J]. Per Med, 2021, 18: 9-19.
[5]	Chen SH, Lin F, Zhu JM, et al. An immune-related lncRNA prognostic model in papillary renal cell carcinoma: a lncRNA expression analysis[J]. Genomics, 2021, 113: 531-540.
[6]	Zhang Y, Mou C, Shang M, et al. Long noncoding RNA RP11-626G11.3 promotes the progression of glioma through miR-375-SP1 axis[J]. Mol Carcinog, 2020, 59: 492-502.
[7]	唐一君, 王文龙, 李江丽, 等. LncRNA RP11-686D22.10与乳腺癌患者生存期相关并影响乳腺癌细胞系的增殖和侵袭[J]. 基础医学与临床, 2023, 43: 1023-1029.
[8]	You B, Sun Y, Luo J, et al. Androgen receptor promotes renal cell carcinoma (RCC) vasculogenic mimicry (VM) via altering TWIST1 nonsense-mediated decay through lncRNA-TANAR[J]. Oncogene, 2021, 40: 1674-1689.
[9]	Tian P, Wei J X, Li J, et al. LncRNA SNHG1 regulates immune escape of renal cell carcinoma by targeting miR-129-3p to activate STAT3 and PD-L1[J]. Cell Biol Int, 2021, 45: 1546-1560.
[10]	Hu G, Ma J, Zhang J, et al. Hypoxia-induced lncHILAR promotes renal cancer metastasis via ceRNA for the miR-613/206/ 1-1-3p/Jagged-1/Notch/CXCR4 signaling pathway [J]. Mol Ther, 2021, 29: 2979-2994.
[11]	Chen M, Wei X, Shi X, et al. LncRNA HIF1A-AS2 accelerates malignant phenotypes of renal carcinoma by modulating miR-30a-5p/SOX4 axis as a ceRNA[J]. Cancer Biol Med, 2021, 18: 587-603.
[12]	Jiang Y, Zhang H, Li W, et al. LINC01426 contri-butes to clear cell renal cell carcinoma progression by modulating CTBP1/miR-423-5p/FOXM1 axis via interacting with IGF2BP1[J]. J Cell Physiol, 2021, 236: 427-439.
[13]	Xia D, Chen Z, Liu Q. Circ-PGC increases the expres-sion of FOXR2 by targeting miR-532-3p to promote the development of non-small cell lung cancer[J]. Cell Cycle, 2021, 20: 2195-2209.
[14]	Gao B, Wang L, Zhang Y, et al. miR-532-3p suppresses cell viability, migration and invasion of clear cell renal cell carcinoma through targeting TROAP[J]. Cell Cycle, 2021, 20: 1578-1588.
[15]	Chen H, Liu Y, Liu P, et al. LINC01094 promotes the invasion of ovarian cancer cells and regulates the Wnt/β-catenin signaling pathway by targeting miR-532-3p[J]. Exp Ther Med, 2021, 22: 1228.doi: 10.3892/etm.2021.10662.

敲减lncRNA RP11-626G11.3通过调控miR-532-3p抑制人肾癌细胞系的增殖和迁移

Knockdown of lncRNA RP11-626G11.3 inhibits proliferation and migration of human renal carcinoma cell lines through regulating miR-532-3p

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 15

相关文章 15

编辑推荐

Metrics

本文评价

[1]	肖艳红, 姜明东, 林叶远, 冉灿, 梁博. 灯盏花乙素抑制人前列腺癌细胞系PC-3的增殖和迁移[J]. 基础医学与临床, 2024, 44(9): 1229-1235.
[2]	姚安军, 陈凌子, 金惠仙. 二十二碳六烯酸抑制人结肠癌细胞系HT-29增殖[J]. 基础医学与临床, 2024, 44(8): 1107-1112.
[3]	郑红, 陈晓霞, 韩李周, 陈苗, 皇甫娟. 降低lncRNA-RMRP表达抑制人肺癌细胞系A549的增殖和侵袭[J]. 基础医学与临床, 2024, 44(7): 974-978.
[4]	曹清文, 祁琳, 禹博, 田晨晨, 袁海宁, 王越. 红景天苷促进人血管内皮细胞系EA.hy926增殖与迁移[J]. 基础医学与临床, 2024, 44(7): 925-930.
[5]	张鹏举, 李杰, 张梦迪, 孙少科, 许寅喆. KAT8通过增强METTL3表达促进结直肠癌细胞系增殖[J]. 基础医学与临床, 2024, 44(7): 931-939.
[6]	高寅洁, 童安莉. 醛固酮产生腺瘤中细胞死亡和增殖机制[J]. 基础医学与临床, 2024, 44(6): 758-762.
[7]	王婷婷, 萧宁, 林佃新, 董海涛. 大蒜素抑制口腔癌细胞系CAL27的增殖[J]. 基础医学与临床, 2024, 44(5): 673-676.
[8]	贾安娜, 郭金鑫, 张璇, 战世佳, 于永波, 郭永丽, 常艳. TMEFF1对神经母细胞瘤细胞系增殖的调控[J]. 基础医学与临床, 2024, 44(5): 637-644.
[9]	宋可, 宋柯, 李静宇, 马伟, 杨晓葵. 小鼠卵母细胞减数分裂中心粒蛋白SAS-6的表达和亚细胞分布[J]. 基础医学与临床, 2024, 44(5): 651-657.
[10]	梁香存, 魏小雨, 梁健, 王庆, 耿广. 安罗替尼通过调控miR-16-5p/PD-1轴抑制人非小细胞肺癌细胞系增殖并促进凋亡[J]. 基础医学与临床, 2024, 44(4): 503-512.
[11]	陆凯, 陆建菊, 郭文利, 黄建棋, 李志华. lncRNA VIM-AS5在人乳腺癌细胞系中的表达及对乳腺癌细胞增殖和迁移的影响[J]. 基础医学与临床, 2024, 44(4): 447-453.
[12]	郭泓江, 徐也婷, 张迪雅, 仇佳星, 王钰铖, 鞠瑞, 郭磊. 羧胺三唑乳清酸盐对人胰腺癌细胞系增殖及脂肪酸合成代谢的影响[J]. 基础医学与临床, 2024, 44(4): 440-446.
[13]	李娜, 李涛, 杨冬梨, 姚媛. 和厚朴酚抑制人脂肪间充质干细胞增殖[J]. 基础医学与临床, 2024, 44(4): 483-488.
[14]	张婧, 杨自更, 蔡文琴, 曹维维, 韦红梅, 薛茜茜, 吴宾. 抑制抗增殖蛋白2增强非小细胞肺癌细胞系A549对厄洛替尼敏感性[J]. 基础医学与临床, 2024, 44(3): 325-332.
[15]	安琪, 齐光照, 韩超. 桃叶珊瑚苷抑制人肝癌细胞系HepG2增殖[J]. 基础医学与临床, 2024, 44(3): 333-338.